Why TFFP and MNKD are Important:
I placed a similar post on this topic yesterday on the NRXP board, but it is equally relevant here. One of the more interesting aspects of following RLFTF and NRXP is their collaboration with each other, and also with other companies. Being relatively small entities, they essentially become a considerable force by partnering up. This also affords investors a window into the development of their products. This isn’t seen with BP where everything is done in house, and behind closed doors. Case in point are the collaborations with TFFP and MNKD. If you go back to the MondoBiotech AG patent #8178489, dated May 15, 2012, you will see that it included freeze drying in the claims. That was 9 years ago. Now fast forward to the present. NRXP is working with TFFP and MNKD, because their freeze drying and encapsulation technologies are patented. If NRXP is successful in applying the TFFP, and MNKD technologies to Zyesami, it will extend, enable and/or broaden the patent protection for this version of aviptadil. From an investing standpoint, you want your money in a product or service that enjoys exclusivity as long as possible. From the recent NRXP conference, Jonathon Javitt:
“We also hope that the formulation work we've done to create ZYESAMI, which is our proprietary stable form of aviptadil, will yield patents that provide additional protection. Lastly, we've announced partnerships with two companies TFF and Mannkind, who have extensive experience in training peptides such as ours into dry powder room temperature stable products that have long-term patent protection.”
It is also in RLFTF’s interest that these product developments are fruitful, through the collaboration agreement with NRXP. So far, it looks like a positive win/win situation to me. ~ Raven, Y@h00 RLFTF finance conversations
